Interstitial Lung Abnormality
Interstitial lung abnormality (ILA) is a term used to describe subtle, often early changes in the supporting tissues of the lungs that are seen on CT but were not the reason the scan was ordered. ILAs may represent mild scarring, inflammation, or other changes in the lung’s framework. Some ILAs remain stable over time, while others can progress to interstitial lung disease. Identifying ILA is important because it can be an early warning of conditions that benefit from monitoring or treatment.
What is it?
The interstitium of the lung is the supporting framework of tissue that surrounds the air sacs (alveoli) and small airways. It contains a network of connective tissue, small blood vessels, and lymphatic channels that help support gas exchange. Interstitial lung abnormality refers to subtle changes in this framework—such as fine lines, small areas of scarring, mild thickening of the supporting tissues, or limited ground-glass opacity—that are seen on chest CT in patients who were not known to have interstitial lung disease and for whom the scan was performed for another reason. By definition, ILA findings involve a portion of the lungs (commonly described as more than 5% of any lung zone) and are not explained by another clear cause such as recent infection or fluid overload.
ILAs can have many possible causes. Some represent early or mild forms of interstitial lung disease, including idiopathic pulmonary fibrosis, fibrotic forms of nonspecific interstitial pneumonia, smoking-related interstitial changes, and lung involvement of connective tissue diseases such as rheumatoid arthritis or scleroderma. Other ILAs reflect exposures—such as occupational dust (asbestos, silica), bird antigens, mold, certain medications, or radiation. Some are related to aging and may be relatively stable, while others reflect inflammation, healed infection, or chronic aspiration. In a portion of patients, an underlying cause cannot be identified despite evaluation.
The clinical significance of ILA depends on several factors. Important features on imaging include whether the changes are mostly fibrotic (containing reticular lines, traction bronchiectasis, or honeycombing) or non-fibrotic, where they are located in the lungs, and how extensive they are. Fibrotic ILA, particularly when located in the lower and outer parts of the lungs, is more likely to progress over time and is associated with a higher risk of developing into more clinically apparent interstitial lung disease. Personal factors—such as age, smoking history, occupational exposures, family history of interstitial lung disease, and presence of autoimmune or connective tissue disease—also influence how the finding is interpreted.
Many patients with ILA have no symptoms at the time the finding is identified. When symptoms occur, they often develop gradually and may include mild shortness of breath with exertion, dry cough, or reduced exercise tolerance. As ILA progresses to interstitial lung disease, symptoms typically become more noticeable and may include more significant breathing difficulty, persistent cough, fatigue, and, in advanced cases, low oxygen levels.
Chest CT, particularly high-resolution CT (HRCT), is the primary tool for identifying and characterizing ILA. Pulmonary function testing measures how well the lungs are working and may show changes such as a restrictive pattern or reduced diffusing capacity. Blood work for autoimmune and connective tissue disease is often performed, since lung involvement can sometimes be the first sign of these conditions. In selected cases, bronchoscopy, bronchoalveolar lavage, or surgical biopsy may be considered. Comparing current imaging with prior studies is particularly important to assess for stability or progression.
Important to Know
Management of ILA is individualized and depends on the imaging features, the patient’s symptoms, exposures, and overall health. The first step is determining whether the finding represents an early or mild interstitial lung disease, an exposure-related change, a manifestation of a systemic condition, or a stable finding unlikely to progress.
Important general measures include smoking cessation, avoidance of relevant occupational or environmental exposures, treatment of acid reflux when present, vaccinations to reduce respiratory infections, and treatment of associated medical conditions such as autoimmune disease. Pulmonary rehabilitation may help patients with breathing symptoms.
Monitoring is an important part of care. Many patients with ILA—particularly those with non-fibrotic or limited findings—are followed with repeat imaging and pulmonary function testing over time to detect any progression early. Patients with imaging features suggesting higher risk (such as fibrotic changes) are often followed more closely. When ILA progresses or evolves into a specific interstitial lung disease, treatment is tailored to the diagnosis and may include immunosuppressive or antifibrotic medications, particularly under the care of a pulmonologist with expertise in interstitial lung disease.
Care is typically coordinated by pulmonologists, primary care clinicians, and, when relevant, rheumatologists. Imaging findings are interpreted alongside the patient’s full clinical picture rather than in isolation.
Red flag symptoms include rapidly worsening shortness of breath, significant low oxygen levels, severe chest pain, coughing up blood, persistent fever, or sudden severe respiratory symptoms. These warrant prompt or urgent medical evaluation, as they may indicate worsening lung disease, infection, or another serious condition.